In the first clinical trial of a PD-1 mAb for cancer patients conducted by The Johns Hopkins Hospital, objective response was observed in multiple cancer types, including melanoma, renal cell cancer, and non-small-cell lung cancer. This evidence concerns the gene PDCD1 and cancer.